Cytokinetics, Incorporated (NASDAQ:CYTK)‘s stock had its “overweight” rating restated by analysts at Piper Jaffray Companies in a report issued on Tuesday, The Fly reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 121.35% from the company’s current price.

A number of other brokerages also recently issued reports on CYTK. Seaport Global Securities reissued a “buy” rating and issued a $24.00 price objective on shares of Cytokinetics, in a research note on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $25.00 price objective (up from $24.00) on shares of Cytokinetics, in a research note on Friday, October 6th. HC Wainwright set a $26.00 price objective on Cytokinetics, and gave the company a “buy” rating in a research note on Thursday, August 3rd. ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $21.00 price objective on shares of Cytokinetics, in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $20.27.

Shares of Cytokinetics, (NASDAQ CYTK) traded down $2.97 during trading hours on Tuesday, hitting $8.13. The stock had a trading volume of 6,746,989 shares, compared to its average volume of 525,706. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60. Cytokinetics, has a 12 month low of $9.80 and a 12 month high of $17.20.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. The company had revenue of $6.18 million for the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative return on equity of 62.64% and a negative net margin of 172.27%. equities research analysts forecast that Cytokinetics, will post -2.4 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/21/cytokineticss-cytk-overweight-rating-reiterated-at-piper-jaffray-companies.html.

In other Cytokinetics, news, SVP Bradley Paul Morgan sold 118,330 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $15.00, for a total transaction of $1,774,950.00. Following the completion of the sale, the senior vice president now directly owns 63,107 shares of the company’s stock, valued at approximately $946,605. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $12.94, for a total value of $55,124.40. Following the sale, the insider now directly owns 17,982 shares of the company’s stock, valued at $232,687.08. The disclosure for this sale can be found here. Insiders have sold a total of 178,223 shares of company stock valued at $2,639,239 over the last three months. Corporate insiders own 7.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of CYTK. State of Alaska Department of Revenue bought a new stake in Cytokinetics, during the 2nd quarter worth approximately $109,000. Bank of Montreal Can bought a new stake in Cytokinetics, during the 2nd quarter worth approximately $126,000. Municipal Employees Retirement System of Michigan bought a new stake in Cytokinetics, during the 2nd quarter worth approximately $132,000. State Board of Administration of Florida Retirement System increased its holdings in Cytokinetics, by 38.4% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 14,778 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 4,103 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Cytokinetics, by 5.1% during the 3rd quarter. Wells Fargo & Company MN now owns 15,627 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 760 shares in the last quarter. 71.92% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

The Fly

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.